Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
67
AVDL Quote, Financials, Valuation and Earnings
Last price:
$21.64
Seasonality move
:
6.07%
Day range:
$21.64 - $21.64
52-week range:
$6.38 - $23.57
Dividend yield:
0%
P/E ratio:
299.90x
P/S ratio:
8.56x
P/B ratio:
21.62x
Volume:
--
Avg. volume:
2.5M
1-year change:
153.4%
Market cap:
$2.1B
Revenue:
$169.1M
EPS (TTM):
-$0.01
Analysts' Opinion
-
Consensus RatingAvadel Pharmaceuticals Plc has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 5 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $21.83, Avadel Pharmaceuticals Plc has an estimated upside of 0.89% from its current price of $21.64.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $20.00 representing 7.58% downside risk from its current price of $21.64.
Fair Value
-
According to the consensus of 5 analysts, Avadel Pharmaceuticals Plc has 0.89% upside to fair value with a price target of $21.83 per share.
AVDL vs. S&P 500
-
Over the past 5 trading days, Avadel Pharmaceuticals Plc has underperformed the S&P 500 by -0.61% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Avadel Pharmaceuticals Plc does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Avadel Pharmaceuticals Plc has grown year-over-year revenues for 6 quarters straight. In the most recent quarter Avadel Pharmaceuticals Plc reported revenues of $77.5M.
Earnings Growth
-
Avadel Pharmaceuticals Plc has grown year-over-year earnings for 8 quarters straight. In the most recent quarter Avadel Pharmaceuticals Plc reported earnings per share of $0.00.
Enterprise value:
2.1B
EV / Invested capital:
--
Price / LTM sales:
8.56x
EV / EBIT:
457.62x
EV / Revenue:
8.33x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
56.25x
Price / Operating cash flow:
57.83x
Enterprise value / EBITDA:
252.45x
Gross Profit (TTM):
$234.8M
Return On Assets:
-0.14%
Net Income Margin (TTM):
-0.11%
Return On Equity:
-0.34%
Return On Invested Capital:
-0.23%
Operating Margin:
2.5%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $8.5M | $138.2M | $248.5M | $50M | $77.5M | |
| Gross Profit | $6M | $127M | $234.8M | $43.9M | $80.5M | |
| Operating Income | -$136.2M | -$64M | $4.5M | -$327K | $1.9M | |
| EBITDA | -$133.8M | -$62M | $8.2M | $708K | $3.1M | |
| Diluted EPS | -$2.16 | -$0.77 | -$0.01 | -$0.03 | $0.00 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $205.8M | $113.2M | $172.3M | $127.3M | $172.2M | |
| Total Assets | $264.1M | $145.8M | $203.1M | $158.3M | $199.4M | |
| Current Liabilities | $17.6M | $41.5M | $54.1M | $42.8M | $62.5M | |
| Total Liabilities | $165.1M | $158.2M | $93M | $83.6M | $101.2M | |
| Total Equity | $99M | -$12.4M | $110.1M | $74.7M | $98.2M | |
| Total Debt | $143.5M | $137.3M | $54.3M | $35.7M | $36.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$122.2M | -$82M | $37M | -$7.7M | $23.3M | |
| Cash From Investing | -$54.7M | $66M | $9.2M | $5.4M | -$8.8M | |
| Cash From Financing | $168.7M | -$7.7M | $4.9M | $1.4M | $2.6M | |
| Free Cash Flow | -$122.2M | -$82M | $36.8M | -$7.7M | $23.3M | |
AVDL
Sector
Market Cap
$2.1B
$25.8M
Price % of 52-Week High
91.81%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
-0.32%
-1.67%
1-Year Price Total Return
153.4%
-21.92%
Beta (5-Year)
1.314
0.499
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$21.64
200-day SMA
Buy
Level
$15.68
Bollinger Bands (100)
Buy
Level
17.26 - 22.6
Chaikin Money Flow
Buy
Level
9.1M
20-day SMA
Buy
Level
$21.59
Relative Strength Index (RSI14)
Buy
Level
61.58
ADX Line
Buy
Level
47.78
Williams %R
Neutral
Level
-54.5455
50-day SMA
Buy
Level
$21.52
MACD (12, 26)
Buy
Level
0.05
25-day Aroon Oscillator
Buy
Level
80
On Balance Volume
Neutral
Level
230.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-0.5177)
Sell
CA Score
(Annual)
Level (-1.8265)
Sell
Beneish M-Score
(Annual)
Level (1.5481)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (4.1804)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (9)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Stock Forecast FAQ
In the current month, AVDL has received 0 Buy ratings 5 Hold ratings, and 0 Sell ratings. The AVDL average analyst price target in the past 3 months is $21.83.
-
Where Will Avadel Pharmaceuticals Plc Stock Be In 1 Year?
According to analysts, the consensus estimate is that Avadel Pharmaceuticals Plc share price will rise to $21.83 per share over the next 12 months.
-
What Do Analysts Say About Avadel Pharmaceuticals Plc?
Analysts are divided on their view about Avadel Pharmaceuticals Plc share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Avadel Pharmaceuticals Plc is a Sell and believe this share price will drop from its current level to $20.00.
-
What Is Avadel Pharmaceuticals Plc's Price Target?
The price target for Avadel Pharmaceuticals Plc over the next 1-year time period is forecast to be $21.83 according to 5 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 5 analysts rate the stock a Hold.
-
Is AVDL A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Avadel Pharmaceuticals Plc is a Hold. 5 of 5 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of AVDL?
You can purchase shares of Avadel Pharmaceuticals Plc via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Avadel Pharmaceuticals Plc shares.
-
What Is The Avadel Pharmaceuticals Plc Share Price Today?
Avadel Pharmaceuticals Plc was last trading at $21.64 per share. This represents the most recent stock quote for Avadel Pharmaceuticals Plc. Yesterday, Avadel Pharmaceuticals Plc closed at $21.64 per share.
-
How To Buy Avadel Pharmaceuticals Plc Stock Online?
In order to purchase Avadel Pharmaceuticals Plc stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get AVDL Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
AVDL
Sector
P/E ratio
299.90x
23.35x
PEG ratio
0.00x
-0.01x
P/B ratio
21.62x
1.78x
Price / LTM sales
8.56x
1.55x
Growth Metrics
AVDL
Sector
Revenue growth
54.86%
3.74%
Earnings growth
100.73%
11.14%
Revenue (5-year growth)
23.35%
6.38%
Earnings forecast
$0.18
-$0.19
Profitability
AVDL
Sector
Profitability FY 2024
$153.8M
$2.6M
Return on invested capital
-0.23%
-32.91%
Return on assets
-0.14%
-29.56%
Return on equity
-0.34%
-38.66%
Earnings Date
Last Earnings Date
Nov
4
Next Earnings Date
Mar
2
Estimated Next Earnings Date
Feb
3
Balance Sheet
AVDL
Sector
Total cash
$91.6M
$25.2M
Short term investments
$22.4M
$24.1M
Total assets
$265.8M
$72.8M
Long term debt
$36.6M
$2.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
73
HYMC alert for Feb 19
Hycroft Mining Holding Corp. [HYMC] is up 3.81% over the past day.
Buy
57
GLBE alert for Feb 19
Global-e Online Ltd. [GLBE] is up 4.19% over the past day.
Sell
37
ACLS alert for Feb 19
Axcelis Technologies, Inc. [ACLS] is down 1.71% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
